Search results
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 2 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Unknown London
Mountain View Telegraph· 4 days agoYou already know. Unknown London.
Astra's Enhertu delays breast cancer in patients with low HER2 levels
Reuters· 6 days ago, opens new tab Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast...
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
InvestorPlace· 3 days agoThis however holds true for high-quality blue-chip and growth stocks. On the other hand, in an...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 5 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta